drugset / Trial / NCT01105429
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with type 2 diabetes.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BMS-820132 | Unknown | 0.3 mg | Oral |
| Comparator | BMS-820132 | Unknown | 1 mg | Oral |
| Comparator | BMS-820132 | Unknown | 3 mg | Oral |
| Comparator | BMS-820132 | Unknown | 10 mg | Oral |
| Comparator | BMS-820132 | Unknown | 30 mg | Oral |
| Comparator | BMS-820132 | Unknown | 75 mg | Oral |
| Comparator | BMS-820132 | Unknown | 150 mg | Oral |
| Comparator | BMS-820132 | Unknown | 300 mg | Oral |